|
Video: What is a Stock Split?
|
|
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for women's cancers. Co. is focused on developing therapies for the treatment of breast cancer. Co.'s wholly owned, primary product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist and a selective ER degrader. Co. is evaluating OP-1250 in a dose escalation and expansion trial for the treatment of ER-positive, human epidermal growth factor receptor 2-negative breast cancer. According to our OLMA split history records, Olema Pharmaceuticals has had 0 splits. | |
|
Olema Pharmaceuticals (OLMA) has 0 splits in our OLMA split history database.
Looking at the OLMA split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Olema Pharmaceuticals shares, starting with a $10,000 purchase of OLMA, presented on a split-history-adjusted basis factoring in the complete OLMA split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/20/2020 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$48.90 |
|
End price/share: |
$11.20 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-77.10% |
|
Average Annual Total Return: |
-35.61% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$2,290.52 |
|
Years: |
3.35 |
|
|
|
|
|